| Undifferentiated Sarcoma studied in …STUDIED_INderived10 of 58show all (up to 200) |
|---|
| → studied in | NCT02923778Phase 2 · active not recruiting Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery · condition mapped ONTOLOGY_EXACT · 58 trials mapped (25 active) | — | — | Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06422806Phase 3 · recruiting Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas · condition mapped CURATED_BROADER · 58 trials mapped (25 active) | — | — | Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07823491Phase 3 · not yet recruiting Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall · condition mapped CURATED_BROADER · 58 trials mapped (25 active) | — | — | Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07802652Phase 2 · not yet recruiting Doxorubicin With or Without DT-7012 in Advanced Soft Tissue Sarcoma · condition mapped ONTOLOGY_EXACT · 58 trials mapped (25 active) | — | — | Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03307616Phase 2 · active not recruiting Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery · condition mapped CURATED_BROADER · 58 trials mapped (25 active) | — | — | Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07817095Phase 2 · not yet recruiting SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma · condition mapped ONTOLOGY_EXACT · 58 trials mapped (25 active) | — | — | Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05711615Phase 1 · recruiting Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma · condition mapped CURATED_BROADER · 58 trials mapped (25 active) | — | — | Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05918640Phase 1/Phase 2 · recruiting Lurbinectedin in FET-Fused Tumors · condition mapped CURATED_BROADER · 58 trials mapped (25 active) | — | — | Undifferentiated Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06820957Phase 2/Phase 3 · active not recruiting Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body · condition mapped CURATED_BROADER · 58 trials mapped (25 active) | — | — | Undifferentiated Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05827614Phase 1 · terminated Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications · condition mapped ONTOLOGY_EXACT · 58 trials mapped (25 active) | — | — | Undifferentiated Pleomorphic Sarcoma | 1 | Observed | clinicaltrials | graph → |